Efficacy of tranexamic acid in bleeding pediatric trauma patients in emergency department | ||
| ALEXMED ePosters | ||
| Article 131, Volume 3, Issue 2, June 2021, Pages 62-63 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2021.80647.1182 | ||
| Author | ||
| Moemen Mohamed Bakry* | ||
| Department of emergency medicine faculty of medicine Alexandria University Egypt | ||
| Abstract | ||
| Pediatric injuries are the main cause of death among children in the United States. Up to 70% of pediatric patients even die before reaching a specialized trauma center. Pediatric injuries represent the majority of hospital admissions and visits to Emergency Department (ED). The physical and psychological needs of any traumatized child and his family must be considered, as any minor injuries may have a long-term impact physically and mentally, and could impair children’s quality of life. TXA is an antifibrinolytic drug used to reduce surgical bleeding and the need for perioperative blood transfusion. TXA is reversibly bind to lysine-binding receptors on plasminogen, displacing plasminogen from the surface of fibrin and reducing the conversion of plasminogen to plasmin. Thus help to prevent fibrin and clot degradation and preserve the fibrin matrix framework. Aim of the Work The aim of this study is to evaluate the effect of early use of tranexamic acid (TXA) on outcomes of pediatric trauma patients in the Emergency Department. | ||
| Keywords | ||
| Tranexamic acid; pediatric trauma; bleeding | ||
|
Supplementary Files
|
||
|
Statistics Article View: 142 |
||
